Players in the global preimplantation genetic diagnosis (PGD) market have found it exceptionally difficult to expand their geographical reach due to a wide presence of local clinics. However, the market has an opportunity to grow, if it finds a way to tackle this restraint. For instance, smaller companies such as Genea Ltd., Reproductive Genetic Institute, Genesis Genetics, and Reprogenetics LLC are focused towards developing improved technologies for preimplantation genetic diagnosis for several other applications. Companies are also aiming at collaborating with various research institutes and other organizations for developing enhanced embryo technologies, observes Transparency Market Research in its new research report.
According to the research report, the opportunity in the global preimplantation genetic diagnosis market is expected to be worth US$118.0 mn by 2020. Between the forecast years of 2014 and 2020, the global market is expected to expand at a CAGR of 6.3%. Amongst the various types of tests available in the global preimplantation genetic diagnosis market, the human leukocyte antigen or HLA testing segment will witness an impressive CAGR of 9.5% during the forecast period. Geographically, North America preimplantation genetic diagnosis market will grow at a significant CAGR of 7.3% between 2014 and 2020.
Growing Rate of Infertility Triggers Adoption of PGD
“High prevalence of delayed pregnancies is the primary factor fueling the growth of preimplantation genetic diagnosis market”, states the lead author of this report. Rising age bracket of pregnant women has not only reduced the chances of conceiving but also raised the risk of fetal abnormalities, stillbirth, and miscarriages. With an increasing number of women opting for delayed pregnancies due to changing lifestyles and mindsets, the demand for in vitro fertilization (IVF) along with preimplantation genetic diagnosis (PGD) has been on the upswing. These techniques mitigate the risk of fetal abnormalities or any other complications during the course of pregnancy to a large extent.
The formidable rise in the number patients suffering from genetic diseases such as diabetes, breast cancer, asthma, and congenital heart diseases amongst others have become leading causes of morbidity and mortality over the past few years. Couples suffering from these diseases are known to predispose these genes to the unborn offspring, thus endangering its life. In the light of these facts, several to-be parents are opting for PGD cycles for ensuring a healthy fetus. The overall market is also being driven by unhealthy lifestyles that are marred with habits such as excessive smoking and alcohol intake, which has significantly contributed towards decreased fertility. Thus, several couples that are unable to conceive are opting for IVF and PGD.
View exclusive Global strategic Business Report : http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=427
Expensive PGD Processes Hinders Market Growth
The high cost of preimplantation genetic diagnosis along with in vitro fertilization that comes with a long list of expensive medications and hospital stays is hindering the growth of the global market. The uncertainty of a conclusive effect despite the high cost is also expected to restrain the overall market in the coming years. Furthermore, the need to repeat the expensive procedures in case of failure is yet another factor discouraging several patients. The global preimplantation genetic diagnosis market is also being hampered by the poor insurance coverage for IVF and PGD processes. Thus, the niche pool of patients is further dissuaded by the poor medical assistance in several regions.
The aforementioned review is based on Transparency Market Research’s latest report, titled “Preimplantation Genetic Diagnosis Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 – 2020.”